Medical Condition News

RSS

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

Medtronic CoreValve System IDE for transcatheter aortic valve implantation receives FDA approval

Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) conditional approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol to begin evaluating the Medtronic CoreValve System for transcatheter aortic valve implantation (TAVI).

15 Oct 2010

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.

15 Oct 2010

Pericytes regulate blood-brain barrier

While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

AstraZeneca launches new campaign on depression through Facebook and Twitter

AstraZeneca is launching a new campaign called "Take on Depression" through a "Take on Depression" Facebook page and a @FaceDepression Twitter feed to support, educate, and inspire those affected by bipolar depression and major depressive disorder (MDD), also known as depression.

15 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

$Spinal fractures remain undiagnosed and untreated$

Spinal fractures remain undiagnosed and untreated

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

15 Oct 2010

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approvals from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for the generic versions of Hyzaar® Tablets, 50 mg/12.5 mg and 100 mg/25 mg, and Cozaar® Tablets, 25 mg, 50 mg and 100 mg, both antihypertensives.

15 Oct 2010

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

Discovery Laboratories, Inc. today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has completed and the results from the study will be presented at the upcoming North American Cystic Fibrosis Conference (NACFC; October 21-23, 2010).

15 Oct 2010

New development of genetic tool to speed discovery of novel genes involved in cancer

Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes.

15 Oct 2010

New implantable pressure sensor for patients with cataract and glaucoma

AcuMEMS, Inc. today announced the development of a new sensor for wireless intraocular pressure (IOP) monitoring of patients with co-incident cataract and glaucoma. Successful animal studies confirm the precise delivery of the implantable pressure sensor into the eye where synthetic intraocular lenses (IOL) are inserted for cataract treatment.

15 Oct 2010

GI Dynamics' EndoBarrier therapy to treat type 2 diabetes and obesity granted European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.

15 Oct 2010

Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment

Emerging Healthcare Solutions, Inc. eagerly anticipates the results of the first FDA-approved human embryonic stem-cell treatment on a patient with spinal cord injuries, which began this week.

15 Oct 2010

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

15 Oct 2010

Study highlights need to address overuse, underuse of colorectal cancer screening tests

Only one-fifth of primary care physicians in the US follow practice guidelines for colorectal cancer screening for all the tests they recommend, according to Dr. Robin Yabroff from the National Cancer Institute and her colleagues. About 40 percent followed guidelines for some of the tests they recommended and the remaining 40 percent did not follow guidelines for any of the screening tests they recommended.

15 Oct 2010

GfK HealthCare: RRMS patients anticipate availability of new oral therapies

Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.

15 Oct 2010

Chest compression-only method of CPR better than standard CPR

Heart attack patients whose hearts have stopped beating and who receive cardiopulmonary resuscitation (CPR) from bystanders fare better if their resuscitators skip the rescue breaths and do only chest compression, according to a study led by researchers at Washington University School of Medicine in St. Louis.

15 Oct 2010

UCLA study sheds light on roots of schizophrenia, autism

UCLA scientists have discovered that exposing fetal neurons to higher than normal levels of a common immune protein leads to abnormal brain development in mice.

15 Oct 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

Medical Condition News

Access receives first MuGard prescriptions and reimbursement

Medtronic CoreValve System IDE for transcatheter aortic valve implantation receives FDA approval

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Pericytes regulate blood-brain barrier

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

AstraZeneca launches new campaign on depression through Facebook and Twitter

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Spinal fractures remain undiagnosed and untreated

Mylan granted FDA approvals for generic Hyzaar and Cozaar ANDAs

Discovery Labs to present lucinactant Phase 2a clinical study results at NACFC Conference

New development of genetic tool to speed discovery of novel genes involved in cancer

New implantable pressure sensor for patients with cataract and glaucoma

GI Dynamics' EndoBarrier therapy to treat type 2 diabetes and obesity granted European CE mark approval

Emerging Healthcare anticipates results of FDA-approved human embryonic stem-cell treatment

A new therapeutic approach for cancer

Study highlights need to address overuse, underuse of colorectal cancer screening tests

GfK HealthCare: RRMS patients anticipate availability of new oral therapies

Chest compression-only method of CPR better than standard CPR

UCLA study sheds light on roots of schizophrenia, autism

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News